Randomized phase II study comparing Gemcitabine versus TS-1 for advanced bile duct cancer
Phase of Trial: Phase II
Latest Information Update: 24 May 2017
At a glance
- Drugs Gemcitabine (Primary) ; Gimeracil/oteracil/tegafur (Primary)
- Indications Biliary cancer
- Focus Therapeutic Use
- 26 Jun 2012 Planned end date changed from 1 Jul 2013 to 1 Jan 2014 as reported by University Hospital Medical Information Network - Japan.
- 26 Jun 2012 Additional lead trial centres identified as reported by ClinicalTrials.gov.
- 29 Dec 2009 Status changed from planning to recruiting as reported by University Hospital Medical Information Network - Japan.